The Quarter Cleared Both Our Upgrade Triggers and the Stock Fell 12.5% on a Breakup Nobody Priced

Results vs. Consensus

CVS reported before the open on November 4 and held its call at 8:00 a.m. ET. The print beat consensus on revenue and on earnings, improved the loss ratio by 150 basis points, and carried a reserve contribution of roughly $0.1B, level with the second quarter and far below the first. The stock closed down 12.5%. The scorecard below is the easy part of this note; everything that moved the share price sits in the sections after it.

Consensus for revenue and adjusted EPS is the figure two of three independent compilations report, within a $1.62 to $1.65 range on earnings and a $104.7B to $105.0B range on revenue. No published consensus existed for the medical benefit ratio, segment adjusted operating income or quarterly cash flow, so those rows are measured against the prior year and against the company's own standing guidance.

Year-over-year comparison

The GAAP line is not usable as a growth comparison. The prior-year quarter carried a $5,725M goodwill impairment on the Health Care Delivery reporting unit, which was not deductible for tax, alongside a $320M opioid litigation charge and an $83M clinic closure charge. Those three items are the whole of the swing from a $(3.13) loss to $1.68 of GAAP earnings. Every growth figure below therefore runs on the adjusted basis, with the GAAP line shown only for completeness.

Sequential comparison

The sequential table is where the Health Care Benefits seasonality lives, and reading it without that context will mislead. Aetna's medical benefit ratio rises through the year as deductibles are satisfied and the Medicare book consumes its benefit, so a 390 basis point sequential deterioration at the segment level is the expected shape rather than a deterioration in underwriting. Health Services improved sequentially on both of its lines, and retail grew adjusted operating income 10.8% sequentially even as its gross margin and comparable lines eased.

Quality of Beat/Miss

• Revenue: broad, with one mix caveat. Growth of 5.4% was carried by Health Services at +9.5% and Health Care Benefits at +2.4%, against Pharmacy & Consumer Wellness at (2.0)%. No acquisition closed in the quarter and nine-month acquisition spend was $15M, but the release credits the Rite Aid asset acquisitions completed in the third quarter of 2025 with part of the retail volume and profit growth. The caveat is that Health Services revenue growth is driven by "pharmacy drug mix and brand inflation," which is pass-through dollar growth that carries no margin, and the segment's gross margin fell 20 basis points year over year while its revenue grew 9.5%. Revenue growth at the pharmacy benefit manager is the least valuable revenue growth in this business.
• Margins: sustainable, with a quantified reservation. The 150 basis point medical benefit ratio improvement came on roughly $0.1B of prior-year development, level with the second quarter and down from $1.1B in the first. Unlike the second quarter, management cited no separate prior-plan-year items either, so this is the first quarter this year whose margin gain cannot be attributed to items relating to earlier periods. Retail gross margin expanded 110 basis points to 19.2%. The reservation is Health Services, where gross margin of 5.4% is down from 5.6% and adjusted operating margin of 3.9% is down from 4.2%, on 9.5% revenue growth. Two of the three operating segments are expanding margin; the largest profit pool is not.
• EPS: operational, and slightly better than it looks. Adjusted EPS grew 30.6% while adjusted operating income grew 21.2%. The gap is not financial engineering. Adjusted diluted shares rose 1.5% year over year, to 1,291 million from 1,272 million, which worked against the per-share figure. Most of the gap is leverage over a near-flat interest bill: interest expense fell only 4.7%, so adjusted pre-tax income, which we compute as adjusted operating income less interest plus other income, rose 28.7% to $3,477M from $2,701M. A lower adjusted tax rate adds roughly 4 points: the reported provision plus the tax impact of the non-GAAP adjustments comes to about 22.5% of adjusted pre-tax income, against 25.1% a year ago. The reported effective rate of 23.8% is also below the roughly 24.8% that ran through the first half. No buyback contributed, because there was none.

Revenue assessment. The headline growth rate overstates the underlying expansion of the business, and the understatement runs the other way at the segment level. Consolidated revenue of $108,399M grew 5.4% against a consensus near 1.8%, a 3.5% beat that was worth nothing to the share price. Inside it, Health Services added $4,698M of revenue and $56M of adjusted operating income, a 1.2% incremental margin. Pharmacy & Consumer Wellness lost $716M of revenue and added $157M of adjusted operating income. The company is now worth more when its retail segment shrinks than when its pharmacy benefit manager grows, which is an unusual sentence to write about CVS and is the clearest statement of why the 2027 framing landed as badly as it did.

Margin assessment. Enterprise adjusted operating margin reached 3.87% against 3.36% a year ago, and all three operating segments grew adjusted operating income, though only two expanded margin. The composition matters more than the level. Health Care Benefits moved from a 0.9% adjusted operating margin to 2.5% and supplied $598M of the $735M consolidated improvement in adjusted operating income, so 81% of the dollar gain is Aetna. That is the correct shape for a thesis built on the Aetna repair and the wrong shape for a diversified business, because it means the enterprise result is a single-segment result with two stable businesses attached. Management's own 2027 framework, examined later, makes that concentration explicit rather than accidental.

EPS assessment. At $2.09 against $1.60, adjusted earnings per share rose $0.49, and the gain was delivered with an adjusted share count that grew 1.5% and no repurchase. Nine-month adjusted EPS of $7.24 already exceeds the entire 2025 figure of $6.75 with a quarter left. The full-year floor of at least $8.20 therefore implies fourth-quarter adjusted EPS of $0.96 against $1.09 a year ago, a 12% decline inside a guide the company has just raised. We read that as the same conservatism behind the eight consecutive quarters of beat and raise management counts, rather than as a forecast, but the arithmetic deserves to be visible and nobody put it on the call.

Segment Performance

Key KPIs

Health Care Benefits

This is the quarter the Aetna thesis needed. Adjusted operating income of $912M against $314M is a $598M improvement on revenue growth of only 2.4%, which means essentially all of it came from the loss ratio rather than from scale. The medical benefit ratio of 91.3% improved 150 basis points, and the nine-month figure of 87.8% compares with 90.0% a year ago. Management narrowed the full-year guide to the lower half of 89.75% plus or minus 25 basis points and raised the segment's full-year adjusted operating income floor to at least $5.4B, a $200M increase on the prior mid-point.

The composition is what changed. Through the first half, the improvement was substantially reserve-driven: $1.1B of favourable prior-year development in the first quarter and roughly $500M of 2025-plan-year items in the second, the largest of which related to the exited individual exchange business. Nine-month development of $1.3B against $1.2B at the half implies roughly $0.1B in the third quarter. The ratio improved anyway.

"Across our businesses, we continue to successfully navigate elevated trends that remain above historical levels throughout the industry. But were broadly in line with our expectations. Performance in our Medicare book modestly exceeded our expectations driven by pockets of favorability as a result of strong medical cost management and disciplined pricing. We remain confident in the adequacy of our reserves." — Brian Newman, EVP and Chief Financial Officer

Membership stabilised for a second quarter, at 26,120 thousand against 26,023 thousand at June 30, with Medicare Advantage up 27 thousand sequentially. The year-over-year decline of 583 thousand is almost entirely the individual exchange exit, where commercial insured lives fell from 3,536 thousand to 2,565 thousand, offset by growth in self-insured commercial. Government premiums grew 8.2% while commercial premiums fell 16.9%, which is the mix the company engineered.

Two items work against the segment. Days claims payable of 41.9 is up 0.2 days sequentially, which the release's highlights state, and down 0.6 days from 42.5 a year ago, which only its table shows. The prior-year base is a heavily reserved one, since it followed the $471M Group Medicare Advantage premium deficiency reserve taken in the second quarter of 2025, so we do not read the decline as evidence of thin reserving. It is a number that should stop falling. The second item is the Star Ratings, which gets its own section below because it is the most consequential undiscussed disclosure of the quarter.

Assessment: the pillar we have carried as the core of the bull case finally produced the evidence we said was missing, and it did so in the quarter we had publicly named as the test. The second quarter was larger in dollars, at $2,426M and a $1,118M year-over-year gain. This one is the better result, because it is the one that did not need the reserves. What it does not do is settle 2028, where the newly published Star Ratings cut the share of Medicare Advantage members qualifying for quality bonus payments by twelve points.

Health Services

Revenue of $53,964M grew 9.5% and adjusted operating income of $2,106M grew 2.7%. That gap is the segment's entire story, and it is widening. Gross margin fell to 5.4% from 5.6%, adjusted operating margin to 3.9% from 4.2%, and the nine-month figures are worse still at 5.0% against 5.3% and 3.5% against 3.8%. Pharmacy claims processed grew 1.3% on a 30-day equivalent basis, which is the fastest of the year and an improvement on +0.9% in the second quarter, so this is not a volume problem.

Sequentially the segment improved sharply, with adjusted operating income up 21.5% and gross margin recovering 50 basis points from 4.9% to 5.4%. Management described the quarter as unremarkable in both of the places investors were watching.

"Results in our pharmacy services business were in line with our expectations during the quarter. Including performance in both our 340B business and rebate guarantees. Healthcare delivery also performed as expected. As we continue to drive improvement in the business." — Brian Newman, EVP and Chief Financial Officer

Then came the number that mattered. The full-year 2026 guide of at least $7.25B was reiterated, which implies $1,922M in the fourth quarter against $1,923M a year ago. For 2027, management set a floor of at least $7.0B. That is 3.4% below the 2026 guide and 2.1% below the $7,151M the segment actually earned in 2025. The causes named were a year-over-year decline in 340B, a "less robust selling season" and health plan client membership attrition, partly offset by specialty strength and a second year of improvement in health care delivery.

Assessment: the bear point we tagged as materialising in August did exactly that. A pharmacy benefit manager that grows revenue 9.5% while its gross margin contracts, and that is then guided to earn less in 2027 than it earned in 2025, is a business whose value capture is being competed and legislated away faster than its volume is growing. Management's framing of 2027 as "trough earnings" is a commitment we will hold them to, and the 2028 selling season is the first place it can be tested.

Pharmacy & Consumer Wellness

Revenue of $35,498M fell 2.0% and adjusted operating income of $1,635M grew 10.6%, with gross margin expanding 110 basis points to 19.2% and adjusted operating margin reaching 4.6% against 4.1%. Prescriptions filled grew 1.9% on a 30-day equivalent basis to 470.0 million. The full-year segment guide moved to $6.5B from at least $6.4B, roughly 8% growth on the $6,040M earned in 2025, for a business that was guiding down 5% two years ago. Management's 2027 outlook of low single digit growth would make that year the third consecutive year of earnings growth for the segment.

The reimbursement-model work is visibly converting. Revenue is falling because of "regulatory-related price reductions on certain drugs, the impact of recent generic drug introductions and pharmacy reimbursement pressure," and profit is rising anyway. That is the definition of a repriced business, and it is the pillar we upgraded after the second quarter.

"As you saw in the quarter, our comp scripts, grew 3.9%. But, also, we were also able to take advantage of new opportunities I think GLP ones is another great example Our scripts in GLP ones this quarter grew 23%. And it is because we took action, we made access more affordable, we made it easier for patients to show up ..." — Prem Shah, Group President and incoming Chief Executive Officer of CVS Pharmacy

The crack is in the comp line. Same-store sales turned negative at (0.6)%, with pharmacy at (0.6)% and front store at (0.6)%, against +14.3% a year ago and +2.6% last quarter. Same-store prescription volume decelerated to 3.9% from 7.0%. The mechanical cause is the Rite Aid prescription file lap, which we flagged in August as beginning in the third quarter, and the files were acquired during the third quarter of 2025, so the comparison is now against an inflated base. The quarterly report names a second cause as a forward risk: "Consumer confidence and a decline in consumer discretionary spending, as well as a shift to value, grocery and digital retailers, could drive lower front store sales." Front store revenue fell 0.5% and front store comps fell 0.6%, so the shift described as a risk is already arriving.

Assessment: profit compounded at 10.6% while the top line and the comp both deteriorated, which is exactly what a successful repricing looks like and is also a configuration with a limit. For 2027 management guided only low single digit growth off $6.5B, which concedes the point. This is the business being separated, and the deceleration in its volume metric arrives in the same quarter it is told it will stand on its own.

Corporate/Other

The adjusted operating loss widened to $(459)M from $(383)M. The quarter also carried a $193M contingent guarantee liability relating to the Omnicare bankruptcy, recorded in Corporate/Other operating expenses and excluded from the adjusted figure. The agreements with the Department of Justice and the Unsecured Creditors' Committee were approved by the bankruptcy court in August 2026, and the company determined in the quarter that the sale of Omnicare's assets is probable in the fourth quarter.

Assessment: the $193M is an estimate rather than a ceiling. The agreements provide that the Department of Justice receives a minimum of $440M in total, of which $130M is payable by CVS within two weeks of effectiveness, and CVS guarantees collection of any shortfall against a $310M floor by March 31, 2028. That backstop date sits inside the separation window, which is the kind of detail that becomes a negotiation point when two companies have to agree who carries a legacy liability.

The Separation

Everything above is the quarter. This is the share price. Management opened the call by announcing an intention to separate into two independent publicly traded companies, and the first word of the chief executive's prepared remarks after the greeting was about that rather than about the results.

The supporting investor deck runs to nine slides, two of which are the cover and the cautionary statement. For a separation of a company guiding to at least $420B of revenue, seven slides of substance is thin, and the row headed "Financial policy for each company" contains three bullets and no number.

Management's answer to this is that the relationship already operates at arm's length, which is true and is the most reassuring fact available.

"CVS and Caremark relationships have operated behind a firewall for more than you know, 2 decades. So this is something that we continually do but we continue to be focused on the value proposition that we create to payers" — Prem Shah, Group President and incoming Chief Executive Officer of CVS Pharmacy

The regulatory reading the company did not offer

The stated rationale has four parts: focus, capital allocation, agility and simplicity. The third of those is where the interesting language sits. The separation release lists among the benefits "greater agility to innovate, adopt technology, increase efficiency and proactively adapt to regulatory and other external dynamics." The call never developed that phrase.

The quarterly report filed the same morning does. Under regulatory trends it states that "some states have recently enacted or are considering legislation related to prohibiting pharmacy licensure for pharmacies affiliated with a PBM," and that this "could limit the Company's ability to provide both pharmacy and PBM services within the same state." A separation that places the pharmacies in one company and the pharmacy benefit manager in another eliminates that exposure by construction. Neither the call nor the announcement connected the two documents, and no analyst did either.

Assessment: we do not think the separation is primarily defensive, because a company under regulatory duress does not usually wait eighteen months and does not usually announce from a raised guide. But the filed risk language makes the defensive reading available, which is why it circulated within hours, and management left it unanswered by declining to address the one benefit it had itself listed. The deeper problem is simpler. A breakup is a claim that the parts are worth more apart, and the company published no figure that would let anyone test it.

Guidance & Outlook

Implied fourth quarter: the floors embed a down quarter

Each full-year figure is a floor rather than a point, and management counts eight consecutive quarters of beat and raise. The bridge below is therefore a measure of embedded conservatism rather than a forecast. It is also arithmetic nobody put on the call.

Two figures deserve attention. The Health Care Benefits floor implies a fourth-quarter segment loss of $979M against $676M a year ago, which is the Medicare seasonality the chief financial officer described in August as a first-quarter to fourth-quarter medical benefit ratio step-up of "slightly higher than 950 basis points." It is the expected shape in an unusually large size. And the cash flow floor implies $182M in the fourth quarter against roughly $3.35B a year ago, which is not a forecast of anything; it is a company that has banked all but $182M of its full-year target with three months to go and has chosen not to raise again.

The 2027 framework: what the $0.20 actually bought

Management raised 2027 by exactly what it raised 2026, and said so.

"So you are reading it right, which is we took the guide this year up $0.20, and effectively flowed that through. We had talked about an $8.45 floor next year, so now it is $8.65. Rounded up a penny. So we are at $8.65 next year. That only assumes the offset of dilution in share repo." — Brian Newman, EVP and Chief Financial Officer

The relationship between the two years is therefore unchanged. At the second quarter, $8.44 against a reported 2026 mid-point of $8.00 was 5.5% growth. Today, $8.65 against a reported 2026 floor of $8.20 is 5.5% growth. The 13% figure management quotes measures against an adjusted 2026 baseline that management did not quantify and that we derive at roughly $7.65 from the rounded 13%, which strips out the prior-year development and exited-business items the company does not expect to repeat. Both numbers are honest. They describe different things, and the gap between them is unchanged at roughly $0.55.

What is new is the segment composition, and it is the most important disclosure of the quarter after the separation itself. Management quantified two of three operating segments for 2027 and declined to quantify the third.

The two segments management was willing to put a number on go sideways to slightly down. Everything else, which is to say all of the 13% growth and all of the 5.5% growth depending on which base you use, has to come from Aetna, from below-the-line items and from the share count. We can size the first of those. Reconciling the $8.65 floor to an operating income requirement needs three assumptions, all stated here: interest expense near the $3.0B the nine months annualise to, an adjusted effective tax rate near the 25.3% the 2026 guide implies, and a share count near the 1,289 million in the 2026 guide, since management assumes only dilution offset. On that basis 2027 consolidated adjusted operating income needs to be roughly $17.8B against at least $17.05B in 2026, an increase near $0.8B. With Health Services down $0.25B and retail up roughly $0.13B, Aetna has to supply close to $0.9B, or about 17% growth off the raised 2026 floor.

That is the whole 2027 story. A floor that depends on a single segment growing about 17% in a year management itself describes as having an elevated trend environment, with a pharmacy benefit manager at trough, is a narrower bet than the one on offer in August. It is not a worse number. It is a less diversified one.

The 2028 commitment, in a year the company will not exist in its current form

Management raised its 2025 to 2028 adjusted EPS compound annual growth commitment from "mid-teens" to the high end of mid-teens. Measured from the 2025 actual of $6.75, which is the base management set at its investor day, the table below shows what each rate requires.

Here is the problem with the upgrade. In August, $8.44 and a mid-teens commitment required roughly 18% to 22% growth in 2028. Today, $8.65 and a high-end-of-mid-teens commitment requires roughly 22% to 25%. Raising the back-year target by more than the near-year floor makes the final year harder, not easier. The $0.20 that was flowed through to 2027 was simultaneously taken back at 2028 by the stronger CAGR language.

And the company will separate in the first half of 2028. A 2028 adjusted earnings per share figure for an entity that splits in two during 2028 is unlikely to be reported on a basis comparable to the $6.75 it is measured from. The commitment was strengthened in the same hour it was rendered unverifiable. Nobody on the call asked how the two statements fit together.

Implied quarter-over-quarter ramp: the fourth quarter needs adjusted EPS of at least $0.96 against $7.24 banked, and needs consolidated adjusted operating income of at least $2,549M with a Health Care Benefits segment loss near $979M absorbed inside it.

Street at: consensus entering the print sat at $1.62 to $1.65 for the quarter. The 2027 anchor the Street has carried since August is management's own $8.44, now replaced by $8.65. Aggregated average price targets fell to between $109 and $113 from roughly $115 after the print, with no rating cut identified.

Guidance style: unchanged and still deeply conservative. The full-year adjusted EPS guide has moved from no more than roughly $7.20 at the start of the year to at least $8.20, more than $1.00, and the cash flow outlook has risen more than $5.5B. Every figure is framed as "at least." The chief executive called it a say-do ratio and counted eight quarters of beat and raise, and the fourth-quarter arithmetic above says the ninth is already built in.

Key Topics & Management Commentary

Overall Management Tone: confident and well rehearsed on the separation, specific and unhesitating on the quarter, and conspicuously selective about which forward numbers it would attach to the plan. The posture was the most assured of the three quarters we have covered, and it was also the least complete, because a management team that volunteered 2027 segment floors a quarter early declined to put a single earnings figure behind the structural change it was announcing. Pushback was narrow and concentrated on what the separation costs and what the 2027 floor embeds; both answers were framework-level rather than quantitative.

1. The separation, announced from a raised guide rather than a weak one

The announcement reverses two decades of vertical integration, beginning with the Caremark combination that closed in 2007 and completed with the Aetna acquisition in 2018. The strategic case management made is that integration is worth preserving where it changes outcomes and is overhead everywhere else, and that retail was never truly integrated in the first place.

"And so as we said, CVS Pharmacy has been operating behind a firewall for the last 2 decades. it is always been an arm's length negotiation and structure, which again, just reinforces the fact that there are integration opportunities, but nothing that we cannot solve for with a commercial agreement." — David Joyner, Chairman and Chief Executive Officer

The timing argument rests on strength rather than necessity, and management returned to it repeatedly: eight quarters of beat and raise, leverage at target ahead of schedule, and a retail business guiding to a third consecutive year of growth after guiding down 5% two years ago.

Assessment: the argument is coherent and the evidence for "position of strength" is real and in the filings. The weakness is not the logic but the absence of any financial case. A separation is a claim that two parts are worth more than the whole, and the company published nothing that would allow a shareholder to evaluate that claim before being asked to hold through fifteen to eighteen months of execution.

2. Health Services guided below its own 2025 result, and called it the trough

The pharmacy benefit manager's 2027 floor of at least $7.0B sits below both the 2026 guide of at least $7.25B and the $7,151M the segment earned in 2025. Management put a floor there deliberately, framed it as the bottom, and committed to growth from that point.

"As we thought about next year, Lisa, and looking ahead to 2027, I thought it was important to establish a floor for the HS segment. And that is respectively what we have done today. We are we are we are confident that we would deliver at least 7 billion in HSS, AOI next year That includes the discussions around a year-over-year decline in 340B next year. And the impact of lower Caremark membership, those 2 elements." — Brian Newman, EVP and Chief Financial Officer

The group president who will lead CVS Pharmacy added that a portion of the membership loss is deliberate on the client side rather than competitive, citing the reset in Aetna's own stand-alone Part D book, and pointed to roughly $6B of gross new wins in the 2026 selling season as evidence the franchise still competes.

Assessment: putting a floor on a declining year is better disclosure than leaving it vague, and the trough framing is a testable commitment. But management is again describing the segment's pressures as "transitory dynamics," and the gross margin has not expanded year over year in any quarter of 2026, holding flat in the second and compressing in the third. Calling 2027 the trough is a forecast, not a fact, and the first evidence will be the 2028 selling season rather than any quarterly print before it.

3. The Star Ratings decline that no one mentioned

The press release's operational updates state that "more than 69 percent of Aetna Medicare Advantage members are in 2027 plans rated 4 stars or higher," and that this positions Aetna second among large publicly traded Medicare Advantage organisations. Both statements are true. The comparative is in the quarterly report filed the same morning, not in the release: more than 69% for 2027 plans against more than 81% for 2026 plans, measured the same way, on membership as of September in each year.

The filing also states the mechanism plainly: the 2027 ratings determine which plans "qualify for bonus payments in 2028." Plans at four stars and above receive a 5% increase in benchmark rates, and there is no offsetting penalty below the threshold, so the consequence sits entirely on one side of a single cliff. Roughly twelve percentage points of the Medicare Advantage book crosses to the wrong side of it for the 2028 payment year. The industry enrollment-weighted average overall rating fell from 4.08 to 4.01 across the same cycle, so this is not sector drift.

On the call, star scores appeared only as a tailwind.

"We obviously as you could see, we did mix adjustments to benefits. But beyond that, we made adjustments to our geography, our product mix, We brought leading star scores in the 2027 payment year. We made adjustments to our network, so we had the highest performing providers in the markets where we wanted to perform and we. And we have built robust capabilities around medical cost management." — Steven Nelson, President, Aetna

That statement is accurate. The 2027 payment year is funded by the prior ratings cycle, the one that produced 81%. The newly published cycle lands on 2028.

Assessment: this is the most consequential disclosure of the quarter that received no airtime, and it lands precisely where the thesis is most exposed. Management raised its 2028 earnings growth commitment to the high end of mid-teens in the same hour that a filing disclosed a twelve-point reduction in the share of its Medicare book qualifying for 2028 quality bonus payments. The company has not sized the revenue effect, and until it does, the 2028 target should carry a discount that it currently does not.

4. The buyback restarts, with $11.5B already authorised and untouched

The capital return question we have carried as an open item since initiation was answered without being asked.

"Our execution has significantly strengthened our balance sheet allowing us to achieve target leverage ahead of schedule and will enable us to resume our share repurchase program in the fourth quarter." — Brian Newman, EVP and Chief Financial Officer

The quarterly report shows why this requires no new board action. Two authorisations remain outstanding, from November 2022 and December 2021, with $11,500,000,143 unused. The repurchase table for the three months to September 30 shows zero shares bought in each of July, August and September, with the available balance unchanged at that figure in all three months. Nine-month debt repayment was $4,057M and long-term debt fell to $57,223M from $60,502M at the start of the year. Cash at the parent and unrestricted subsidiaries stood at roughly $5.9B.

Assessment: $11.5B of authorised capacity against a market capitalisation that closed at roughly $103B is 11% of the company, available immediately, at a share price 19% below where it traded in August. The 2027 floor explicitly assumes none of it beyond dilution offset, which makes any real repurchase additive to $8.65 rather than embedded in it. This is the strongest single fact in the bull case and it was given two brief mentions in the prepared remarks, with no dollar figure.

5. Cash flow raised $4.0B, with $182M left to do

Nine-month cash flow from operations of $15,318M compares with $7,249M a year ago. The full-year outlook moved to at least $15.5B from at least $11.5B, an increase of $4.0B in a single quarter and more than $5.5B for the year against the initial outlook. Management attributed the raise to earnings, working capital improvements and "the timing of certain payments."

Assessment: the floor leaves $182M for the fourth quarter against roughly $3.35B a year ago, which tells you the guide is a floor rather than an estimate. The phrase to watch is the timing of certain payments, because working capital that arrives early is working capital that does not arrive later. Nine-month change in operating assets and liabilities contributed $3,556M against a $(453)M drag a year ago, so roughly half the cash flow improvement is working capital rather than earnings. That does not make it less real, but it does make it less repeatable, and the 2027 cash flow guide in February is where it gets tested.

6. Retail profit is compounding and the comp line went negative

Same-store sales of (0.6)% is the first negative comparable in our coverage, against +14.3% a year ago. Same-store prescription volume decelerated to 3.9% from 7.0%. Both are mechanically explained by the Rite Aid prescription file acquisitions completing in the third quarter of 2025, which means the base is now inflated, and we flagged this lap in August as the thing to watch. Profit grew 10.6% through it.

The forward framing was notably more cautious than the result. For 2027, management guided only "low single digits" off the $6.5B 2026 figure, and described the outlook as "maintaining a prudent view of consumer dynamics."

Assessment: the lap is real and the deceleration is arithmetic rather than share loss, since prescriptions filled still grew 1.9% in absolute terms. What is not arithmetic is the front store, where comps of (0.6)% sit against a risk the quarterly report describes as consumers shifting "to value, grocery and digital retailers." The repricing has done its work on margin. The next leg has to come from volume, and volume just decelerated in the quarter the business learned it will be standing alone.

7. The 340B headwind, declared finished before it has finished

The unsized 340B headwind from August was finally bounded, in a manner that is more confident than specific.

"So with respect to 340B, we do not expect this to be a topic we need to discuss going forward. The level of contribution that we have our 2027 plan is an even smaller portion of the HSS segment earnings than it has been historically." — Prem Shah, Group President and incoming Chief Executive Officer of CVS Pharmacy

The chief financial officer added that the business is expected "to largely stabilize by the end of next year." Neither statement carries a dollar figure, and the quarterly report still lists 340B under business uncertainties: "The environment for the federal 340B drug pricing program remains dynamic and may continue to impact the Company's Health Services segment."

Assessment: declaring a headwind closed is a stronger statement than the company has been willing to make on any other open item, and it is unsupported by a number. The honest read is that 340B is now small enough that its decline no longer moves the segment, which is a different claim from the program stabilising. The commitment is useful because it is falsifiable: if 340B is still being cited as a cause in the 2028 guidance, the credibility cost will be real.

8. What replaces integration: commercial agreements, and Health100 goes with retail

The asset split contains one genuine surprise. Health100, the consumer technology platform the chief executive described as "the connective tissue between the 2 organizations," goes to CVS Pharmacy rather than to the company that holds the insurer and the pharmacy benefit manager. Mail pharmacy moves across with it, out of Health Services and into the retail company.

"So we do not need the integration of. In an operating structure, We need to make sure that we are aligned around where we believe that there can be value creation and ensure that there is an appropriate commercial agreement in place to support that. So that is in large part what will be working on over the course of the next 15 to 18 months, is why the mail service is actually inside of CVS Pharmacy because we have reinvented how pharmacy is delivered." — David Joyner, Chairman and Chief Executive Officer

Assessment: putting the consumer engagement layer and mail with the retail company is defensible on the logic that both are consumer-facing fulfilment, and it also puts the asset management describes as the future of the enterprise outside the company management is keeping. Both entities are said to remain committed to Health100. Shared commitment to a platform owned by one party and depended upon by the other is precisely the kind of arrangement that works until the two boards disagree, and there are fifteen to eighteen months in which to write that contract.

9. Specialty stays with the payer, and the logic is the best in the plan

Specialty pharmacy remains with CVS Health alongside Aetna and Caremark. The justification is the clearest strategic argument management made all morning.

"there is 2% of this population that is driving more than 50% of the spend of pharmacy, and it is growing at a rate that is not affordable and it is not sustainable. And so it is why you need all of the levers of classic PBM in order to continue to attack the rising drug cost and the way in which, you know, we create competition. And so we think the synergistic opportunity with the PBM in specialty remains intact." — David Joyner, Chairman and Chief Executive Officer

Assessment: this is the one piece of the split where the integration case is made on economics rather than on organisational theory. Specialty is also the growth engine management named as a 2027 tailwind for a segment otherwise guided down. Keeping it with the payer and the benefit manager is correct, and it means the retail company loses the part of the pharmacy market management describes as growing fastest at the moment it is asked to stand alone on roughly $145B of revenue with a decelerating script comp.

10. Dyssynergies, described rather than counted

Asked about separation costs, the chief executive called them manageable and already contemplated in guidance, and the chief financial officer repeated the point.

"when we looked at the deal, the strategic value created by taking this action is gonna far outweigh any dis synergies. As I look at the run rate AOI impact of any stranded or public company cost, as well as any onetime cost they are they are they are certainly manageable, and in line with other transactions of this type." — Brian Newman, EVP and Chief Financial Officer

The quarterly report is less comfortable. It warns that there is no assurance "that dis-synergy costs, costs of restructuring transactions and other costs incurred in connection with the separation will not exceed CVS Health's estimates," and that the timing depends on "finalization of the capital structure of the new company."

Assessment: management says the costs are contemplated in its guidance and the filing says the estimates may be exceeded, and neither document says what the estimates are. For the two prior transactions management invoked as precedent, Caremark and Aetna, the synergy figures were published at announcement. The absence here is the single most fixable thing on this list, and the February call is the deadline we will hold it to.

11. The securities litigation moving in the background

Not mentioned on the call or in the release. The quarterly report discloses that in August 2026 the court "denied in part and granted in part" the defendants' motion to dismiss the consolidated securities class action, which is premised on allegations of "omissions and misrepresentations relating to the profitability of the Health Care Benefits segment." The stays in the related derivative actions terminated in September 2026, and in October 2026 the board received a supplement to a stockholder demand covering the same conduct.

Separately, the Federal Trade Commission settlement advanced: the public comment period has ended and the settlement now awaits a final order, with the commission's litigation halted pending that outcome.

Assessment: the regulatory item improved and the litigation item got worse, and the call discussed neither. A surviving securities class action about Health Care Benefits profitability is an awkward backdrop for a year in which Health Care Benefits must supply essentially all of the earnings growth. It is not a thesis-breaking fact at this stage, and it belongs on the list of things that get harder to manage across two separating companies.

Analyst Q&A Highlights

The session ran to eleven exchanges from ten analysts, with questioners asked to limit themselves to one each, and the separation dominated it. Two exchanges reached the operating businesses in any depth, on the Health Services floor and on where Medicare Advantage margins now sit, and both are below. Five specific items went unasked across the whole session: the medical benefit ratio, the reserve position and days claims payable, the implied fourth-quarter Health Care Benefits loss, the negative retail comparable, and the Star Ratings. The words "benefit ratio" and "same store" each appear once in the transcript, both in prepared remarks, and "days claims payable" does not appear at all.

The timing of a decision taken from strength rather than necessity

The opening question went straight to why now, and the answer was the clearest articulation of management's case. The response tied the decision to two specific operational recoveries rather than to any external pressure, and explicitly rejected the framing that the company was acting under duress.

Q: "But can we first start with just the timing of this and the rationale You walked through, you know, a number of the components, but if we could just maybe better understand especially the timing aspect."
— Lisa Gill, JPMorgan

A: "And I think that the timing of this decision is saying, you know, now is the time because we are not doing anything out of a distressed decision. We actually are doing it because we actually have healthy balance sheets with appropriate capital allocation opportunities and momentum in each 1 of the businesses that we are operating."
— David Joyner, Chairman and Chief Executive Officer

Assessment: the claim is supported by the filings rather than merely asserted, which is more than most breakup rationales manage. Leverage reached target ahead of schedule, the repurchase authorisation is intact, and three segments grew. The answer does not address the harder question, which is not why now but why at all, and that question was never put directly.

What the 2027 floor embeds, and what it deliberately does not

The most consequential exchange of the call, and the shortest. The question established that the $0.20 raise to 2026 had simply been passed through to 2027 with no additional contribution from the capital return management had just announced for the fourth quarter.

Q: "So given the $0.20 raise to this year's EPS guidance, it does not look like you are assuming much EPS contribution from the resumption of share repurchase in 2027. Can you help us understand that dynamic and whether there are any other offsets embedded in the outlook, including no breakup costs you might incur next year?"
— Andrew Mok, Barclays

A: "So you are reading it right, which is we took the guide this year up $0.20, and effectively flowed that through. We had talked about an $8.45 floor next year, so now it is $8.65. Rounded up a penny. So we are at $8.65 next year. That only assumes the offset of dilution in share repo. So as you can imagine, as cash is back, leverage is where we want it to be. We have got some dry powder to leverage."
— Brian Newman, EVP and Chief Financial Officer

Assessment: confirmation that $8.65 is a pure operating number on a balance sheet carrying $11.5B of authorised and unused repurchase capacity. That is the strongest argument available that the floor is genuinely a floor. The second half of the question, on whether separation costs are embedded in 2027, was not answered.

Where the dyssynergies land and who carries them

One question pressed directly on the operating cost structure, noting that both prior combinations were justified on cost synergies and asking what the reversal costs and where those costs sit. The answer produced no figure and did not specify which company absorbs them.

Q: "I know it is early, but I guess how are you thinking about what the potential financial dissynergies could be? And any color on whether you think they will sit entirely in the newly created CVS Pharmacy business or, I guess, shared or allocated across the 2 businesses?"
— Stephen Baxter, Wells Fargo

A: "As I look at the run rate AOI impact of any stranded or public company cost, as well as any onetime cost they are they are they are certainly manageable, and in line with other transactions of this type. So we are gonna look to offset any run rate costs over time."
— Brian Newman, EVP and Chief Financial Officer

Assessment: the allocation question, which is the one that determines how the retail company's standalone earnings look, was not engaged at all. "In line with other transactions of this type" is a range wide enough to contain any answer. This is the gap that will be filled on the February call or will become a genuine credibility problem.

Capital structure, ratings treatment and deployment after the split

A pointed question anticipated that rating agencies would reclassify the remaining company as a managed care organisation, shifting the governing metric from debt to EBITDA toward debt to capital, and asked whether that constrains the deployable capital discussed at the investor day.

Q: "I assume the rating agencies are now gonna look at CVS Health as a managed care organization, meaning debt to cap versus debt to EBITDA. Wanted to hear how this might impact your leverage versus today. And then we have all been expecting significant share repo into 2027 and beyond. Is there any impact on the company's ability to deploy capital versus that $35 billion of deployable capital opportunity you discussed at the Investor Day kind of post the breakup"
— Justin Lake, Wolfe Research

A: "I can say with a high degree of confidence that both companies will be solid investment grade with strong free cash flow generation. As you mentioned, we will target leverage or debt to cap, metrics that are appropriate for that rating level. ... As I look out to the future and the transaction, I would not see anything getting in the way of our ability to deploy capital going forward."
— Brian Newman, EVP and Chief Financial Officer

Assessment: the answer confirms the direction and declines the arithmetic. An insurer holding company is capitalised differently from a retail-and-services conglomerate, and statutory capital requirements at the insurance subsidiaries constrain what the parent can upstream. Management gave an assurance where a framework was requested, and the deployable capital figure from the investor day was left unreconciled.

Whether the products built on integration survive the separation

A question drawn from twenty years of joint product development asked whether capabilities created by common ownership can persist under contract. The answer laid out the architecture management intends, and is the most specific description of the future operating relationship given all morning.

Q: "How do you think about the potential I do not wanna call them dyssynergies specifically, but the strategic rationale for the overlap going forward between the 2 entities and how that the competitive differentiation that both entities have been able to generate by being together, by being aligned between the store and the PBM that they do not lose that capability going forward."
— Michael Cherny, Leerink Partners

A: "But the unique products that we built over the last you know, 20 years, are things that we are going to be preserved and commercial agreements between the 2 organizations. So we do not need the integration of. In an operating structure, We need to make sure that we are aligned around where we believe that there can be value creation and ensure that there is an appropriate commercial agreement in place to support that."
— David Joyner, Chairman and Chief Executive Officer

Assessment: the substantive reply is that the economics survive as contracts. That is credible for products with clear value to both sides and untested for anything requiring one party to accept lower economics for a joint outcome, which is most of what integration is actually for. The contracts do not exist yet and will be written over fifteen to eighteen months by executives who will shortly run competing companies.

How far through the Medicare Advantage margin journey Aetna actually is

The most direct question of the morning on the operating recovery asked management to confirm where Medicare Advantage margins now sit and whether 2027 reaches the target or merely approaches it.

Q: "It seems like at this point, based on your updated guidance, you probably breached into getting towards I would think, sort of a very low level of profitability back in the Medicare Advantage business. For 2026 inside of the guidance. Just wanted to confirm that. ... Should I read into that anything in terms of where you expect to take the margins for 2027 back toward target, or is this still a multiyear journey in terms of getting back to that 3% to 4% target margin for Medicare Advantage?"
— Scott Fidel, Goldman Sachs

A: "Yeah. I can confirm the business is on. Still on its multiyear journey. But it is ahead of expectations. We are moving into the profitable territory in 2026, so I can confirm that. And then as we look to 2027, we are gonna expand on that for the reasons I indicated earlier."
— Steven Nelson, President, Aetna

Assessment: a clean confirmation that Medicare Advantage returned to profitability in 2026 and that the 3% to 4% target remains multi-year rather than imminent. This is the disclosure that matters most for 2027, since Aetna must supply essentially all of next year's growth, and it is the only forward-looking answer of the call that was both specific and unprompted by the breakup.

Standalone growth algorithms, declined

A direct request for per-company growth frameworks was turned down, with the answer redirected to the enterprise 2028 commitment instead.

Q: "I know that you said 2028 should be on higher end of your range you provided at Investor Day. Are you ready to give any kind of growth algorithms whether on a operating income or EPS for the 2 new companies on a stand alone basis?"
— Ann Hynes, Mizuho

A: "I would just I was thinking back to investor day, and we set out a road map, which was in the mid teens. Which gets us to the 2028 horizon. We are tracking well against that. ... And I. By signaling that we are gonna be at the upper end in the upper end of mid teens by 2028. I just wanted to give the street confidence that we are on track to meet or exceed our expectations."
— Brian Newman, EVP and Chief Financial Officer

Assessment: this is the exchange that explains the share price. A company announcing a breakup was asked what the pieces earn and answered with a consolidated growth rate for a year in which the consolidation ends. The upgrade to the high end of mid-teens was clearly intended as reassurance, and in the absence of any per-company figure it functions as a reminder that the enterprise target and the enterprise structure now expire in the same year.

The 340B contracting question, and a headwind declared finished

A follow-up asked whether the 340B pressure reflects a change in contracting approach and how management has visibility that the drag ends in 2027 rather than extending into 2028. The response bounded the issue by shrinking it rather than by quantifying it.

Q: "Brian made the comment that you have line of sight that it ends in 2027. It does not spill into to 2028. Can you maybe just help me to understand that when I think about what is happening here and why you have line of sight that it is only going to have an impact here in 2026 and 2027."
— Lisa Gill, JPMorgan

A: "So with respect to 340B, we do not expect this to be a topic we need to discuss going forward. The level of contribution that we have our 2027 plan is an even smaller portion of the HSS segment earnings than it has been historically."
— Prem Shah, Group President and incoming Chief Executive Officer of CVS Pharmacy

Assessment: the honest content of the answer is that 340B has shrunk to the point where it no longer moves the segment, which is a materially different claim from the program stabilising. The same morning's filing still carries 340B under business uncertainties. The commitment is at least falsifiable, which is an improvement on the unsized headwind of three months ago.

What They're NOT Saying

1. Any earnings figure for either company: revenue was disclosed for both, and adjusted operating income, EBITDA, margin, free cash flow and capital expenditure were disclosed for neither. A nine-slide deck for a separation of a company guiding to at least $420B of revenue is not a disclosure failure by accident.
2. The Star Ratings comparative: the release gives "more than 69 percent" for 2027 plans with no prior-year figure. The quarterly report gives both, and the comparison is a twelve-point decline from "more than 81%" for 2026 plans, affecting 2028 bonus payments. The selection of which document carries the comparison is a choice.
3. What the separation costs: "manageable, and in line with other transactions of this type" was the only answer to the one direct question, and a second question on whether breakup costs sit in the 2027 outlook went unanswered. The filing simultaneously warns that dyssynergy and restructuring costs may exceed the company's own estimates, which are themselves unpublished.
4. Which company carries the stranded costs: asked directly, not answered. This determines what CVS Pharmacy's standalone earnings look like, and therefore what the piece shareholders will receive is worth.
5. The size and terms of the inter-company commercial agreements: the two standalone revenue estimates sum to roughly $45B more than the consolidated guide, which is revenue flowing between the companies. No term, no pricing, no renewal mechanism, no disclosure of what happens if the two sides cannot agree.
6. The debt split and each company's leverage target: "solid investment grade" is a rating ambition, not a capital structure. The filing names "finalization of the capital structure of the new company" as a condition of completion, so the company does not know either.
7. The implied fourth-quarter Health Care Benefits loss: roughly $979M, against $676M a year ago, embedded in a guide the company raised. Disclosed by arithmetic rather than by statement, and nobody on the call reconstructed it.
8. How the 2028 target is measured after a 2028 separation: management raised a 2025 to 2028 compound growth commitment in the same hour it said the company will split during the first half of 2028. The resulting figure cannot be compared with the $6.75 base it is measured from.
9. The securities class action: survived its motion to dismiss in part in August 2026, on allegations about Health Care Benefits segment profitability, with derivative stays terminated in September and a supplemental stockholder demand received in October. Absent from the call and the release.
10. The regulatory benefit management itself listed: the separation release names adapting to "regulatory and other external dynamics" as a benefit, and the quarterly report names state legislation that could prohibit pharmacy licensure for PBM-affiliated pharmacies. The connection was left for others to make, and they made it within hours.
11. The size of the repurchase: the program resumes in the fourth quarter against $11.5B of unused authorisation. No pace, no target, no dollar figure, and no statement of whether the buyback continues through the separation process.

Market Reaction

• Pre-print setup: closed at $91.41 on November 3, up 15.2% year to date against 10.6% for the S&P 500, up 17.1% over twelve months and up 5.1% over the trailing thirty days. The 52-week closing range entering the print was $70.08 to $110.60.
• Reaction session: the release crossed before the open and the call began at 8:00 a.m. ET, ahead of the 9:30 open. The stock gapped down 6.7% to open at $85.30, then sold through the session to a low of $77.33, down 15.4%, before closing at $79.96, down 12.5% or $11.45.
• Volume: 34.3 million shares against a 30-day average of 8.6 million, four times normal.
• Peer reaction: Elevance closed up 4.9%, Cigna up 3.4% and UnitedHealth up 1.2% on the same session, with the S&P 500 up 1.6%. All three large managed-care peers beat and raised in this quarter's season, as did CVS.
• Where it leaves the year: the $79.96 close sits 0.8% above the December 31, 2025 close of $79.36. One session erased the entire year.

The mechanics are unambiguous and they rule out most of the available explanations. This was not a sector move: managed care rose across the board while CVS fell 12.5%, so any attribution to broad healthcare volatility fails on the tape. It was not the print: revenue beat a consensus looking for 1.8% growth by delivering 5.4%, adjusted earnings beat by 26.7%, and the full-year guide went up for the third consecutive quarter. It was not the 2027 number in isolation either, because $8.65 is higher than the $8.44 the Street had carried since August.

What repriced is the structure. The shape of the session is the evidence: a 6.7% gap at the open, which is the market's first reading of a breakup announcement plus a raised guide, and then further selling through the session to a 15.4% low. Gap moves are reactions to headlines. What follows the gap is the market working through the detail, and in this case the detail was an absence. There is no earnings figure for either company, no debt split, no dyssynergy estimate and no leverage target. Every hour of that session was an hour in which an institutional holder tried to value two businesses from one revenue line each and could not.

Underneath the structural question sits a second, narrower one that is being conflated with it. The pharmacy benefit manager was guided to earn less in 2027 than it earned in 2025, and management named it the trough. In a quarter when every large peer was raising, a company announcing a breakup and a declining profit pool in the same breath will be sold by anyone whose position depended on the integrated growth story. That is a legitimate repricing of a narrower, longer-dated set of outcomes. It is not a 12.5% repricing of earnings power, because earnings power went up on every line of the 2026 guide except Health Services, which held.

Street Perspective

Debate: Is the separation strategic or defensive?

Bull view: the company acted from strength, with eight consecutive beat-and-raise quarters behind it, leverage at target ahead of schedule and all three segments growing. Conglomerate discounts are real, the retail business has been run at arm's length behind a firewall for two decades, and the value-accretive parts of the relationship survive as contracts. Doing this from a raised guide is the opposite of distress.

Bear view: the quarterly report names state legislation that could prohibit pharmacy licensure for pharmacies affiliated with a pharmacy benefit manager, and the separation release lists adapting to regulatory dynamics among its benefits. A split that resolves that exposure by construction, announced without a financial case, reads as a structure chosen for the regulators rather than for the shareholders.

Our take: the bull view is closer, and the bear view is winning the argument because management declined to contest it. A company under genuine regulatory duress does not set an eighteen-month timeline. But the regulatory benefit was listed by the company and then never explained, which left the field to the least charitable reading. The more serious criticism is not the motive; it is that a breakup is a claim about the value of the parts and no figure was published that would let anyone test it.

Debate: Is $8.65 a floor or a ceiling?

Bull view: it assumes no repurchase beyond dilution offset, on a balance sheet with $11.5B of authorised and untouched capacity and a program restarting in the fourth quarter at a share price 19% below August. It embeds a pharmacy benefit manager at what management calls trough and Medicare Advantage only partway through a margin recovery that is running ahead of plan. Everything in the construction points one way.

Bear view: against the reported 2026 floor it is 5.5% growth, the identical relationship management described in August, which means three months of outperformance bought no change in the forward trajectory. The 13% figure is measured against an adjusted baseline management defines. Two of three segments are guided flat to down, and the entire increase depends on one segment growing roughly 17% in an environment management itself calls elevated.

Our take: it is a floor, and the bears are right that it is a narrower one than it was. Our resolution is that the number is probably beaten and the concentration is the real disclosure. A 2027 carried by Aetna alone is a different security from a 2027 carried by three segments, and the right response is a lower multiple on a higher number rather than a lower estimate. That is precisely what we have done.

Debate: What is a shareholder actually going to own in 2028?

Bull view: two focused investment-grade companies, each with strong free cash flow and a dividend, in a $2 trillion market and a $500 billion market respectively. Sum-of-the-parts analysis has long argued the retail and payer assets are worth more apart, and shareholders receive both, tax-free, with the option to hold either.

Bear view: nobody can run that analysis, because the only figure published for each company is revenue. The retail company loses specialty, keeps a decelerating script comp and a negative same-store line, and will derive a large share of its revenue from a contract with its former parent that has not been written. The payer company keeps a pharmacy benefit manager guided below its 2025 earnings and a Medicare book that just lost twelve points of four-star membership share for the 2028 payment year.

Our take: the bears have the better of this one and will keep it until February. The disclosure gap is the entire problem, and it is fixable. The question that will decide the outcome is one management declined to answer: what does CVS Pharmacy earn on roughly $145B of revenue once stranded costs are allocated to it? Until that number exists, the market is being asked to underwrite a breakup on faith, and a 12.5% discount for faith is not an unreasonable price for it to demand. Our disagreement is with the magnitude rather than the direction, because the thing being discounted sits fifteen to eighteen months away while the cash flows being discounted are arriving now.

Model Update Needed

Valuation impact: at the November 4 close of $79.96 and the third-quarter diluted share count of 1,291 million, market capitalisation is roughly $103.2B. Total debt is $60,680M, being $57,223M long term plus $3,457M current, against cash and equivalents of $11,738M, for net debt near $48.9B and an enterprise value near $152.1B. The stock trades at 9.75x management's 2026 floor of $8.20, 9.61x our $8.32, 9.24x the 2027 floor of $8.65, 8.98x our $8.90 and 11.85x the 2025 adjusted actual of $6.75. Nine-month dividends paid of $2,578M annualise to roughly $3.44B, or 3.3% of market capitalisation, with an $11.5B repurchase authorisation now being switched on alongside it. We move our twelve-month fair value to $99 from $104, set at 11.5x management's 2027 floor of $8.65 and rounded down from $99.48, equivalent to 12.1x the 2026 floor, about 23.8% above the November 4 close. The reduction is entirely the multiple: the earnings anchor rose from $8.44 to $8.65, and we cut the multiple by more than that increase to pay for separation execution risk and the unsized 2028 quality bonus headwind.

Thesis Scorecard Post-Earnings

Overall: the operating thesis strengthened and the structural thesis got more complicated, and the market priced only the second. Three of four bull pillars were confirmed on their own stated terms, the bear point about earnings quality moved to contained after two quarters of being right, and the valuation pillar was restored by a 12.5% decline rather than by anything management did. Against that, the pharmacy benefit manager is guided below its 2025 earnings, twelve points of four-star Medicare membership moved to the wrong side of the quality bonus threshold for 2028, and a new structural risk opens with a disclosure deficit attached.

Action: Upgrading to Outperform from Hold, with conviction unchanged at 6 out of 10 and a twelve-month fair value of $99, down from $104. We published two conditions for an upgrade in August, and we judge both met. The first was a third-quarter medical benefit ratio inside the tightened full-year range with prior-year development below $200M. We adjudicate it as met, and the basis matters because the quarterly ratio of 91.3% is not literally inside an annual range of 89.75% plus or minus 25 basis points. Aetna's loss ratio is seasonal and rises through the year, so the test has to run on the full-year measure the trigger named, and on that measure management narrowed the guide to the lower half of the range, better than the midpoint it was tracking to in August. The development condition was met outright at roughly $0.1B against a $200M threshold, and it is the half of the trigger that carried the analytical weight. The second was a capital-return announcement that converts the deleveraging into per-share compounding: the repurchase resumes in the fourth quarter against $11.5B of standing authorisation. Our downgrade condition, that $8.44 be restated as the top of the 2027 range rather than the bottom, did not fire; it was restated as the bottom at $8.65. We hold conviction at 6 rather than raising it because the range of outcomes widened this quarter rather than narrowing, and the upgrade is driven by price and by triggers we published in advance, not by a higher-conviction view of the business. We would move back to Hold if the February guidance places 2027 Health Services below $7.0B, if the fourth-quarter repurchase does not materialise, or if the separation disclosure in February still contains no earnings figure for either company. We would move to Underperform if the company quantifies a 2028 Star Ratings revenue headwind large enough to put the high end of the mid-teens commitment out of reach, or if the separation timeline extends beyond the first half of 2028.